SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is experiencing a notable pullback as Amazon Pharmacy's launch of Novo Nordisk's oral GLP-1 for weight loss, unavailable on HIMS's platform, intensifies competition in the telehealth weight management sector. This, coupled with a recent Bank of America downgrade citing potential margin pressure, has sparked a polarized community debate: many see the stock as "broken," while long-term investors highlight oversold conditions and strong fundamentals as a significant buying opportunity.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is actively trending following positive regulatory feedback that significantly de-risks its lead drug, sonelokimab, by allowing a Biologics License Application filing without additional trials. This pivotal development, coupled with recent analyst upgrades and upcoming investor events, has fueled extensive community speculation about a potential strategic acquisition, with many anticipating substantial upside from the biotech's de-risked asset.

ProShares Trust - ProShares Ultra Bloomberg Natural Gas 2x Shares

ProShares Ultra Bloomberg Natural Gas

ProShares Ultra Bloomberg Natural Gas (BOIL) is trending amidst extreme price plunges, largely driven by persistently warm winter forecasts and ample natural gas supplies. The community is expressing widespread despair over significant losses, with many desperately hoping for an "arctic blast" or "polar vortex" to reverse the devastating trend for this highly volatile, leveraged ETF, while others question its long-term viability.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is trending with heightened anticipation for its J.P. Morgan Healthcare Conference presentation, where updates on Briumvi's robust market adoption and 2026 guidance are highly awaited. Community sentiment is also notably buoyed by recent competitor setbacks that underscore Briumvi's strong profile, leading to active discussions around potential strategic acquisitions and the influence of short positions.

Exxon Mobil Corp. engages in the exploration, development, and distribution of oil, gas, and petroleum products. It operates through the following segments: Upstream, Energy Products, Chemical Products, and Specialty Products. The Upstream segment organizes the exploration of crude oil and natural gas. The Energy Products segment includes fuels, aromatics, and catalyst and licensing. The Chemical Products segment offers petrochemicals. The Specialty Products segment provides finished lubricants, basestocks and waxes, synthetics, and elastomers and resins. The company was founded by John D. Rockefeller in 1882 and is headquartered in Spring, TX.

Exxon Mobil Corp.

Exxon Mobil Corp

Exxon Mobil is trending as the market closely watches unfolding developments in Venezuela, with the US administration signaling that American oil companies could be heavily involved in revitalizing the nation's vast oil reserves. This potential for asset recovery and new investment is fueling bullish sentiment and discussions of significant upside. However, community conversations also highlight widespread concerns regarding market oversupply, political complexities, and the long-term feasibility of such ventures.

Rich Sparkle Holdings Ltd. engages in the provision of financial printing and corporate services. The firm offers typesetting, proofreading, translation, design, and printing of listing documents, financial reports, fund documents, circulars, and announcements. It also delivers advisory services, such as conducting internal control assessment and environmental, social and governance performance evaluation, and other services including provision of co-working space. The company was founded in 2016 and is headquartered in Hong Kong.

Rich Sparkle Holdings Ltd.

Rich Sparkle Holdings Limited

Rich Sparkle Holdings Limited is trending due to recent news of a private placement and a significant acquisition, alongside the expiration of its IPO lock-up period. This low-float Hong Kong stock has ignited a fierce debate within the community, with many anticipating a short squeeze reminiscent of other volatile "China plays," while others warn of a rapid pump-and-dump scenario.

VisionWave Holdings, Inc. engages in the forefront of revolutionizing defense capabilities by integrating advanced artificial intelligence (AI) and autonomous solutions across air, ground, and sea domains. The company was founded on March 20, 2024 and is headquartered in Wilmington, DE.

VisionWave Holdings Inc.

VisionWave Holdings, Inc.

VisionWave Holdings (VWAV) is generating significant buzz following a series of strategic developments in its AI, defense, and drone technology sectors, including recent patent grants and acquisitions. The community is highly bullish, anticipating a major "parabolic" move or short squeeze driven by the stock's extremely low float and high institutional ownership, with many drawing comparisons to past high-growth stocks. Investors are also noting its "Strong Buy" rating from Nasdaq Dorsey Wright and successful pilot programs, signaling strong potential for commercialization and growth.

NovaBay Pharmaceuticals, Inc. engages in the development and sales of scientifically-created and clinically-proven eyecare and skincare. Its products include Avenova, NeutroPhase and DERMAdoctor. The company was founded on January 19, 2000 and is headquartered in Emeryville, CA.

Novabay Pharmaceuticals Inc

Novabay Pharmaceuticals (NBY) is generating significant buzz due to a special cash dividend, the strategic involvement of investor David Lazar, and high short interest fueling short squeeze speculation. The community is sharply divided, with many anticipating substantial upside while others warn of a pump-and-dump. Conversation is also driven by recent filings hinting at a strategic pivot towards blockchain or financial infrastructure, comparing NBY to other low-float, high-volatility plays.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending amid intense community debate surrounding an ICE agent's fatal shooting in Minneapolis, with newly analyzed footage fueling polarizing arguments about justified force versus alleged government overreach. This contentious environment is further amplified by ongoing discussions about the release of "Epstein files" and President Trump's recent engagement with oil executives regarding Venezuela's energy sector. The stock remains highly sensitive to these significant political and social controversies, influencing investor sentiment and trading conversations.

Chevron Corp. engages in the provision of oil and gas energy solutions. It provides crude oil and natural gas, manufactures transportation fuels, lubricants, petrochemicals, and additives, and develops technologies that enhance business and the industry. It operates through the Upstream and Downstream segments. The Upstream segment consists of the exploration, development, and production of crude oil and natural gas, the liquefaction, transportation, and regasification associated with liquefied natural gas, the transporting of crude oil by major international oil export pipelines, the processing, transporting, storage, and marketing of natural gas, and a gas-to-liquids plant. The Downstream segment consists of the refining of crude oil into petroleum products, the marketing of crude oil and refined products, the transporting of crude oil and refined products by pipeline, marine vessel, motor equipment, and rail car, and the manufacturing and marketing of commodity petrochemicals and plastics for industrial uses and fuel & lubricant additives. The company was founded on September 10, 1879 and is headquartered in Houston, TX.

Chevron Corp.

Chevron is a major trending topic as the market processes U.S. involvement in Venezuela's vast oil sector, where the company holds a unique position as the sole U.S. major currently operating. While many in the community anticipate significant long-term opportunities from unlocking these reserves, others temper enthusiasm, highlighting the substantial time and investment required to rebuild infrastructure and potential implications for global oil supply dynamics.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Dare Bioscience, Inc. (DARE) Reports Q3 Loss, Lags Revenue Estimates

Dare Bioscience (DARE) delivered earnings and revenue surprises of +15.15% and -95.00%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Caribou Biosciences, Inc. (CRBU) Reports Q3 Loss, Misses Revenue Estimates

Caribou Biosciences (CRBU) delivered earnings and revenue surprises of +16.67% and -14.34%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Editas Medicine (EDIT) Reports Q3 Loss, Beats Revenue Estimates

Editas (EDIT) delivered earnings and revenue surprises of +26.32% and +365.62%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Sutro Biopharma, Inc. (STRO) Reports Q3 Loss, Tops Revenue Estimates

Sutro Biopharma (STRO) delivered earnings and revenue surprises of -59.52% and +16.52%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Arcellx, Inc. (ACLX) Reports Q3 Loss, Misses Revenue Estimates

Arcellx (ACLX) delivered earnings and revenue surprises of -3.13% and -66.20%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

AC Immune (ACIU) Reports Q3 Loss, Lags Revenue Estimates

AC Immune (ACIU) delivered earnings and revenue surprises of +9.09% and -22.51%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Dare Bioscience, Inc. (DARE) Reports Q2 Loss, Lags Revenue Estimates

Dare Bioscience (DARE) delivered earnings and revenue surprises of +18.18% and -103.68%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Immatics (IMTX) Reports Q2 Loss, Misses Revenue Estimates

Immatics (IMTX) delivered earnings and revenue surprises of -73.68% and -62.32%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Editas Medicine (EDIT) Reports Q2 Loss, Tops Revenue Estimates

Editas (EDIT) delivered earnings and revenue surprises of -53.66% and +320.94%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Misses Revenue Estimates

C4 Therapeutics (CCCC) delivered earnings and revenue surprises of +2.63% and -0.57%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Daré Bioscience, Inc. operates as a healthcare company, which engages in the development and commercialization of pharmaceutical products in women's reproductive health. Its products include Ovaprene and Topical Sildenafil. The company was founded by Sabrina Martucci Johnson, Lisa Walters-Hoffert and Roger L. Hawley on November 28, 2005 and is headquartered in San Diego, CA.

Dare Bioscience Inc

Yes — Rates Move Meaningfully Lower

Short-Term Dip, No Lasting Impact

No — Mostly Political Noise

Other – Comment Below

President Trump says he’s directing $200 billion into mortgage bond purchases to bring down rates and improve housing affordability. With questions around execution, authority, and real market impact, do you think this move will actually lower mortgage rates in 2026?

Will Trump’s Mortgage Bond Plan Actually Lower Rates in 2026?

DARE
Dare Bioscience Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest DARE News

DAREDare Bioscience Inc